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Amyotrophic lateral sclerosis (ALS) is a fatal, neurodegenerative condition characterized by loss of motor
neurones and progressive muscle wasting. There is no diagnostic test for ALS therefore robust bio-
markers would not only be valuable for diagnosis, but also for the classiﬁcation of disease subtypes,
monitoring responses to drugs and tracking disease progression. As regulators of gene expression,
microRNAs (miRNAs) are increasingly used for diagnostic and prognostic purposes in various disease
states with increasing exploration in neurodegenerative disorders. We hypothesize that circulating
blood-based miRNAs will serve as biomarkers and use miRNA proﬁling to determine miRNA signatures
from the serum of sporadic ALS patients compared to healthy controls and patients with diseases that
mimic ALS. A number of differentially expressed miRNAs were identiﬁed in each set of patient com-
parisons. Validation in an additional patient cohort showed that miR-206 and miR-143-3p were
increased and miR-374b-5p was decreased compared to controls. A continued change in miRNA
expression persisted during disease progression indicating the potential use of these particular miRNAs
as longitudinal biomarkers in ALS.
 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Amyotrophic lateral sclerosis (ALS) is a clinical subtype of motor
neurone disease, a fatal, neurodegenerative condition characterized
by selective loss of motor neurones and progressive muscle
wasting, leading to death within 2e5 years of symptom onset. It is
one of the most common adult onset neurodegenerative diseases
with a prevalence of 6e8 per 100,000 (Mcdermott and Shaw, 2008).
ALS is a complex disease with multiple pathogenic mechanisms
having been proposed including: oxidative stress, excitotoxicity,
mitochondrial dysfunction, protein aggregation, defective axonal
transport, dysregulated endosomal trafﬁcking, neuroinﬂammation,
and dysregulation of RNA processing (reviewed by Ferraiuolo et al.
(2011)). The majority of diagnosed ALS cases are sporadic ALS
(sALS; 90%) with no obvious family history, however, in recent years
several genes have been described in familial ALS, which accountTranslational Neuroscience,
outh Yorkshire S10 2HQ, UK.
Inc. This is an open access articlefor 5%e10% of all ALS cases (Byrne et al., 2011). Themost common of
these is an intronic hexanucleotide repeat expansion in the gene
chromosome 9 open reading frame 72 (C9orf72) which has been
shown to decrease mRNA levels (Baumer et al., 2014; Dejesus-
Hernandez et al., 2011; Renton et al., 2011), and accounts for
w40% of all familial ALS and w7% of sALS cases (Majounie et al.,
2012). Other commonly associated ALS genes include mutations
in SOD1 leading to a toxic gain of function and protein aggregation
(Kaur et al., 2016) and mutations in TARDBP and FUS causing dys-
regulation of RNA processing and protein aggregation (Lattante
et al., 2013).
There is no single, pure diagnostic test for ALS, with diagnosis
currently dependent upon referral to a neurologist for assessment.
There is an average delay of 1 year from symptom onset to a
conﬁrmed diagnosis, typically midway through the patient’s disease
course (Cellura et al., 2012; Zoccolella et al., 2006). In such a rapidly
progressive disease this delay is a signiﬁcant obstacle to potential
therapeutic strategies (Cloutier et al., 2015). ALS is clinically hetero-
geneous, with multiple subtypes associated with different survival
times and overt symptoms. Robust biomarkers would be valuable for
the initial diagnosis, the classiﬁcation of various subtypes of disease,under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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progression (Turner et al., 2009). In addition, the use of biomarkers
may help to establish suitable patient subsets for clinical and ther-
apeutic development trials (Cloutier et al., 2015; Nzwalo et al., 2014;
Turner and Benatar, 2015; Turner et al., 2009). Blood is an attractive
source of biomarkers interacting with every tissue in the body, and
identifying changes in bloodmRNA/protein has previously been used
to reﬂect pathological changes in neurodegenerative diseases
(Borovecki and Habek, 2010; Sharp et al., 2006). Sample collection is
straight-forward, relatively noninvasive, and part of standard clinical
practice.
As master regulators of gene expression, microRNAs (miRNAs)
are increasingly used for diagnostic and prognostic purposes in
various disease states including cancer (Ma and Weinberg, 2008),
with increasing application in the ﬁeld of neurodegenerative dis-
orders. miRNAs are a novel class of small, noncoding RNA molecule
predicted to posttranscriptionally regulate at least one third of
human genes (Lewis et al., 2005) acting via binding to comple-
mentary regions of targeted mRNA (Bartel, 2009). An increasing
number of studies have demonstrated the existence of miRNAs in
the blood at detectable levels (Chen et al., 2008; Daniels et al., 2014;
Sethi et al., 2013). miRNAs from the blood are exceptionally stable,
resisting RNase degradation, different storage temperatures, low/
high pH conditions, and multiple freeze thaw cycles making them
ideal as potential biomarkers (Botta-Orﬁla et al., 2014; Chen et al.,
2008; Jin et al., 2013; Ren et al., 2016). Recently, serum-based
miRNA screening identiﬁed 24 signiﬁcantly downregulated miR-
NAs in premanifesting ALS mutation carriers, up to 2 decades or
more before their symptomatic disease onset (Freischmidt et al.,
2014). miR-206 was upregulated in serum derived from ALS
patients as well as in SOD1G93A mice compared to control mice
(Toivonen et al., 2014). In a larger patient cohort, the expression of
miR-338-3p was signiﬁcantly upregulated in the serum of sALS
patients, potentially helping in the understanding of sALS patho-
genesis and early diagnosis biomarkers (de Felice et al., 2014).
Clearly, the role of miRNAs and their potential use as biomarkers in
ALS requires further investigation.
In this study we hypothesized that blood based miRNAs will
serve as informative biomarkers useful in sALS diagnosis, moni-
toring of disease progression and/or prognosis prediction. Initial
miRNA proﬁling was used to determine miRNA signatures from the
serum of sALS patients compared to healthy controls and patients
with diseases that mimic sALS providing a number of differentially
expressed miRNAs identiﬁed in each set of patient comparisons.
Validation of miR-206, miR-143-3p, and miR-374b-5p was
completed in an additional sALS patient/control cohort with their
expression investigated during disease progression to establish
their potential use as longitudinal biomarkers in ALS.Table 1
Discovery patient cohort
Group n Age (range) Gender (M:F)
sALS 27 64 (44e77) 15:12
Control 25 65 (49e77) 12:13
Noninﬂammatory neuropathy 7 65 (42e77) 5:2
Myopathy 7 66 (48e77) 3:4
Inﬂammatory neuropathy 8 59 (28e75) 5:3
Structural spinal disorders 6 57 (42e72) 4:3
Myasthenia gravis 8 68 (52e87) 4:3
Key: sALS, sporadic amyotrophic lateral sclerosis.2. Material and methods
2.1. Discovery study patient cohort
All blood samples were taken in the morning following an
overnight fast and collected in serum-separating tubes and stored
at 4 C. Serum was harvested fromwhole blood within 24 hours of
the sample collection and stored at 80 C until miRNA extraction
was completed. All sALS samples were taken at the time of diag-
nosis before starting on a course of riluzole (Rilutek). The disease
mimic group was divided into 5 diagnostic categories as follows:
(1) Noninﬂammatory neuropathies
(2) Myopathies (including inclusion body myositis and
polymyositis)(3) Inﬂammatory neuropathies (including GuillaineBarré syndrome
and multifocal motor neuropathy)
(4) Structural spinal disorders
(5) Myasthenia gravis
All ALS patients were classiﬁed as sALS. The average age at
disease onset in the sALS cohort (n ¼ 27) was 64 years (range
44e77 years), and the average age of controls (n ¼ 25) was 65 years
(range 49e77). Details of the full discovery cohort are shown in
Table 1.2.2. Validation study patient cohortdQiagen custom quantitative
PCR (qPCR) arrays
For validation of qPCR arrays, blood samples were collected from
a further patient cohort. Towiden the applicability of the test and to
determine if the biomarkers remained valid whether or not the
individual had fasted, not all blood samples were fasted. In addition,
samples from patients on riluzole were also collected and the
possible effect of the treatment determined. All sALS samples were
taken at the time of diagnosis or within 3 months. The average age
of the validation sALS cohort (n ¼ 23) was 66 years (range
39e88 years). The average age of control subjects (n ¼ 22) was
62 years (range 41e79) (Table 2). Further patient details are pro-
vided in Supplementary Table 1.2.3. Longitudinal study patient cohort
The longitudinal study patient cohort consisted of 22 sALS
patients (6F:16M) where 2 samples at different time points were
taken from the same individual. Eleven patients were recruited
from the validation patient cohort although an additional 11 new
patients were recruited to the longitudinal study. The average age
of the sALS cohort was 61 years (range 31e85 years) on ﬁrst
sample collection. Patients did not fast, and some patients (11/22)
were already on a prescribed course of riluzole at the time of
their ﬁrst blood sample being taken. All blood samples were
collected as previously described. The ﬁrst patient samples
(baseline) were taken within 3 months of diagnosis with the
second sample (latest) taken at least 3 months after diagnosis
(Table 3).2.4. miRNA extraction
miRNA from patient serum samples were extracted using the
Circulating Nucleic Acid Isolation Kit (Norgen Biotek) according to
manufacturer’s protocols using 1 mL serum samples. This method
of miRNA extraction provided robust, consistent miRNA levels from
serum samples.
Table 2
Validation patient cohort
Group n Age (range) Gender (M:F)
sALS 23 66 (39e88) 13:10
Control 22 62 (41e79) 11:11
Key: sALS, sporadic amyotrophic lateral sclerosis.
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The expression level of 750miRNAswas determinedusing human
miRNA TaqMan Low Density Arrays (TLDAs) (Applied Biosystems) in
27 sALS patients, 25 controls, and 36 ALS mimic patients. Samples
were divided into batches of 10 containing 3 sALS patients, 3 controls,
and 4 disease mimics for each experimental run to minimize any
batch speciﬁc effects.
The TLDAs were run on an ABI 7900HT qPCR machine using
Sequence Detection System software v2.3 according to the manu-
facturer’s recommended methodology. The NormFinder algorithm
was applied to identify the optimal normalization miRNAs from a
set of candidates consistently expressed across all samples
(Andersen et al., 2004). NormFinder ranks candidate normalizers
according to their expression stability, the average of 8 of the most
stable and highly expressed miRNAs was then applied to the
data set as a normalization factor and used to calculate the delta
cycle threshold (CT) value.
2.6. Qiagen custom qPCR array selectiondvalidation study
A panel of 27 miRNA candidate markers were used to design
custom qPCR arrays from Qiagen, selected by the following criteria:
(1) p-value <0.05 upon comparison of sALS patients with the
control group and (2) miRNAs identiﬁed as signiﬁcantly different
(p < 0.05) in more than one comparison of sALS patients to disease
mimic groups. Validation experiments using miScript custom qPCR
arrays were carried out using serum obtained from 23 sALS patients
and 22 neurologically normal controls.Table 3
Longitudinal study patient cohort identifying gender, disease onset site, riluzole state, ag
Longitudinal study patient cohort
Gender Disease onset site Riluzole naïve Age at symptom
onset (y)
F Bulbar Yes 71.4
M Lower limb Yes 41.8
M Lower limb Yes 67.5
F Lower limb Yes 84.8
M Lower limb Yes 49.7
M Bulbar Yes 70.5
M Upper limb Yes 29.8
F Upper limb Yes 67.2
M Lower limb Yes 40.2
M Mixed Yes 59.2
M Mixed No 59.3
F Upper limb No 63.2
M Bulbar No 59.3
M Lower limb No 46.5
M Bulbar No 56.5
F Lower limb No 53.7
M Lower limb No 74.2
F Upper limb No 77.0
M Upper limb No 70.8
M Bulbar No 71.8
M Upper limb No 30.4
M Lower limb Yes 61.12.6.1. Qiagen reverse transcription
Custom miScript miRNA PCR arrays containing the 27 miRNA-
speciﬁc miScript Primer Assays were used, with 12 patient sam-
ples per array being investigated (6 control and 6 sALS). In brief,
5 mL of extracted RNA were used in separate miScript RT reactions
(37 C for 60 minutes, 95 C for 5 minutes, followed by 4 C)
according to manufacturer’s instructions. Samples were diluted
5-fold in RNase-free water prior to preampliﬁcation.
2.6.2. Qiagen preampliﬁcation and quantiﬁcation by real-time
polymerase chain reaction
5 mL diluted cDNA was preampliﬁed according to the manufac-
turer’s protocol with relevant miScript preampliﬁcation reaction
components including the relevant miScript PreAMP Primer Mix
(custom designed or in house prepared). Cycling conditions were as
follows: 95 C for 15 minutes, 2 cycles of 30 seconds at 94 C,
60 seconds at 55 C and 60 seconds at 70 C followed by 10 cycles of
30 seconds at 94 C, 3 minutes at 60 C. Ampliﬁed cDNAwas diluted
5-fold in RNase-free water prior to being added to the miScript
qPCR reaction mix containing 2 QuantiTect SYBR Green PCR
master mix, universal primer followed by the addition of sample to
the custom miScript miRNA PCR array.
The qPCR arrays were run on a CFX384 BioRad Real-Time PCR
System using Bio-RAD CFX Manager software according to the
manufacturer’s recommended conditions. First, relative expression
of mature miRNAs was calculated using the comparative CT (2 
DDCT) method and the running of each plate was assessed by the
analysis of internal plate controls. The average of 3 prechosen
normalization control miRNAs (miR-17-5p, miR-223-3p, miR-24)
was applied to the data set as a normalization factor (per plate)
used to calculate the delta CT value.2.7. Longitudinal study
miRNAs signiﬁcantly different in patients compared to con-
trols were investigated over a period of time with samples taken
from patients at diagnosis (baseline, within 3 months) and at a
later time point at least 3 months after diagnosis (Table 3).e at symptom onset, baseline sample age, and the time between samples
Baseline
sample age (y)
Time since diagnosis
to baseline sample (mo)
Time since diagnosis
to latest sample (mo)
75.6 0.9 8.3
43.9 0.1 13.3
78.0 0.0 3.3
85.8 0.3 11.9
51.2 0.2 10.7
70.9 1.1 5.9
31.5 0.8 10.9
68.4 0.2 11.3
43.1 0.6 13.0
59.6 1.2 11.0
59.9 0.2 10.1
65.8 2.3 14.0
59.9 1.4 17.9
48.7 1.4 18.3
57.1 3.0 10.6
57.0 0.0 12.6
75.3 1.4 10.5
77.8 1.7 7.4
71.2 1.4 8.6
72.5 1.9 5.5
31.9 1.8 8.1
62.8 0.3 7.5
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described.
2.8. Bioinformatic/statistical analysis
Relative expression of mature miRNAs was calculated using
high-throughput qPCR package in R statistical computing envi-
ronment for the TLDA analysis (Dvinge and Bertone, 2009) or
through the comparative CT (2  DDCT) method for speciﬁc miS-
cript validation experiments. Qlucore Omics Explorer program
(Qlucore AB, Sweden) was used to visualize the discovery cohortFig. 1. Qlucore output: example PCA plots and heatmaps, t-tests p  0.05. (A) ALS (yellow
ﬂammatory neuropathy (green). Abbreviations: ALS, amyotrophic lateral sclerosis; PCA, pri
legend, the reader is referred to the Web version of this article.)data. For each study, all statistical analysis between 2 comparison
groups was carried out using the unpaired 2-tailed t-tests.
Nonparametric KruskaleWallis tests were carried out to test
whether statistical relevance was present between the different
miRNA expression across the 3 different patient groups (bulbar,
upper, and lower limb onset). Where statistical relevance was
present a pair wise ManneWhitney U-test was employed to iden-
tify where statistical differences were present. All statistical anal-
ysis was carried out in GraphPad Prism 6 (GraphPad Prism Inc,
USA). p-values smaller than 0.05 were considered statistically sig-
niﬁcant. *p < 0.05; **p < 0.01; ***p < 0.001.) versus control (blue), (B) ALS versus myopathy (turquoise), (C) ALS versus nonin-
ncipal component analysis. (For interpretation of the references to color in this ﬁgure
Table 4
Differentially expressed miRNAs in multiple patient comparisons
Comparison Number of cases Number of
miRNA
Average
p-value
ALS v Con 27 v 25 14 0.0296
ALS v Inﬂam 27 v 8 17 0.0302
ALS v MG 27 v 8 14 0.0176
ALS v Myop 27 v 7 28 0.0242
ALS v NonInﬂam 27 v 7 25 0.0222
ALS v Struct 27 v 6 16 0.0303
Con v Inﬂam 25 v 7 13 0.0220
Con v MG 25 v 8 39 0.0229
Con v Myop 25 v 7 26 0.0243
Con v NonInﬂam 25 v 7 18 0.0264
Con v Struct 25 v 6 20 0.0277
Inﬂam v MG 8 v 8 41 0.0226
Inﬂam v NonInﬂam 8 v 7 24 0.0217
Inﬂam v Struct 8 v 6 13 0.0237
Inﬂam v Myop 8 v 7 13 0.0310
MG v Myop 8 v 7 13 0.0264
MG v NonInﬂam 8 v 7 22 0.0269
MG v Struct 8 v 6 21 0.0257
Myop v NonInﬂam 7 v 7 14 0.0255
Myop v Struct 7 v 6 11 0.0248
Noninﬂam v Struct 7 v 6 14 0.0297
Differentially expressed miRNAs are deﬁned as those having a p-value 0.05 be-
tween the 2 comparable patient groups.
Key: ALS, amyotrophic lateral sclerosis patient group; Con, control subject group;
Inﬂam, inﬂammatory neuropathy patient group;MG,myasthenia gravis patient group;
miRNA, microRNA; Myop, myopathy patient group; NonInﬂam, noninﬂammatory
neuropathy patient group; Struct, structural spinal disorders patient group; v, versus.
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3.1. miRNA proﬁling in discovery cohort
Each patient cohort sample size for each study was determined
based on sample availability at the time of testing and correlates
with other similar published work (Freischmidt et al., 2013;
Toivonen et al., 2014). miRNA proﬁling was completed in a well-
deﬁned discovery cohort of 27 sALS patients, 25 controls, and
36 ALS mimic patients with various neuromuscular conditions.
Based on the signiﬁcantly expressedmiRNA therewas some overlap
between sALS patients and controls (Fig. 1A). However, a clear
distinction between sALS and myopathy patients (Fig. 1B) and sALS
and noninﬂammatory neuropathy (Fig. 1C) was apparent. Further
distinctions between sALS and other mimic diseases were identi-
ﬁed and the number of differentially expressed miRNAs in each set
of patient comparisons is shown in Table 4. Comparing miRNA lists
revealed differential expression of miRNAs which appeared in more
than one comparison between sALS and control/mimic diseases
(sALS vs. control group, 12 miRNAs; sALS vs. noninﬂammatory
neuropathy patient group, 5 miRNAs; sALS patient group vs.
myopathy patient group, 8 miRNAs; sALS patient group vs. in-
ﬂammatory neuropathy patient group, 5 miRNAs; sALS patient
group vs. structural spinal disorders patient group, 8 mRNAs; sALS
patient group vs. myasthenia gravis patient group, 4 miRNAs)
suggesting an increased likelihood for them to be sALS speciﬁc
(Table 5). These miRNAs were taken forward for validation in an
additional patient cohort. In total, 27 miRNA formed the basis of the
panel used for validation studies with 3 normalization controls,
miRNAs, miR-17-5p (0.008), miR-223-3p (0.013), and miR-24
(0.004), which were identiﬁed as the top 3 ranked miRNAs stably
expressed in all the comparisons made according to NormFinder.
3.2. Validation of miRNA biomarkers in serum
Of the 12 miRNAs differentially expressed between sALS and
control subjects in the discovery cohort, the validation studies
found 3 of them; miR-206, miR-143-3p, and miR-374b-5p to be
signiﬁcantly differentially expressed in an additional patient cohort
comparing 23 sALS and 22 control subjects (Fig. 2). miR-206 and
miR-143-3p were signiﬁcantly increased in sALS patients compared
to controls, whereas miR-374b-5p was signiﬁcantly decreased in
the same comparison. Analysis was carried out to investigate the
expression of the 3 candidate miRNAs in the 3 patient subgroups
according to site of disease onset (bulbar n ¼ 9, upper n ¼ 7, and
lower limb n ¼ 7 onset). No signiﬁcant difference in miR-206
(p ¼ 0.795), miR-143-3p (p ¼ 0.245), or miR-374b-5p (p ¼ 0.537)
between the patient groups was identiﬁed.
3.3. Riluzole treatment does not affect miRNA expression
No signiﬁcant difference in expression of miR-206, miR-143-3p
and miR-374b-5p was identiﬁed between the 2 patient groups
(riluzole naïve [n ¼ 13] and riluzole treated [n ¼ 10]), demon-
strating that riluzole has no effect on the expression of these 3
speciﬁc miRNAs in serum (Fig. 3). Further analysis was completed
to examine the expression of the other 24 candidate miRNA
investigated in the validation study to identify whether riluzolewas
affecting miRNA expression levels on the whole when comparing
sALS patients and controls. When comparing riluzole naïve patients
(n ¼ 10) to controls (n ¼ 22), 2 additional signiﬁcantly expressed
miRNAs were identiﬁed; miR-744-5p (p-value 0.035) and miR-
134-5p (p-value 0.015) which were not differentially expressed
when comparing patients prescribed riluzole to controls. However,
when comparing patients prescribed riluzole (n ¼ 13) to controls(n ¼ 22), 2 additional signiﬁcantly expressed miRNAs were identi-
ﬁed, miR-381-3p (p-value 0.035) and miR-146b-3p (p-value 0.029),
which were not differentially expressed when comparing riluzole
naïve patients compared to controls.3.4. miR-143-3p and miR-374b-5p are consistently changed from
diagnosis throughout sALS patients disease course
Having established that riluzole does not appear to have a
signiﬁcant effect on miR-206, miR-143-3p, and miR-374b-5p
expression, the 2 patient groups (riluzole naïve and riluzole
treated) were combined and the analysis of the candidate miRNAs
over time was investigated. Results showed a signiﬁcant increase
in miR-143-3p in serum samples taken from sALS patients later in
their disease (>3 months) compared to serum samples taken from
patients at diagnosis. By contrast miR-374b-5p was signiﬁcantly
decreased in serum samples taken from sALS patients later in their
disease (>3 months) compared to serum samples taken from pa-
tients at diagnosis (Fig. 4). Whilst miR-206 was increased over
progression of the disease, the change over time did not reach
signiﬁcance. Additionally, no signiﬁcant difference was seen in the
expression of the 3 miRNAs in the group of 11 riluzole naïve pa-
tients of the longitudinal study compared with their subsequent
later sample where patients were prescribed riluzole (data not
shown).
Furthermore analysis was carried out to investigate the
expression of the 3 candidate miRNAs in the 3 patient subgroups,
divided according to site of disease onset (bulbar n¼ 5, upper n¼ 6,
and lower limb n ¼ 9 onset). Only levels of miR-143-3p
were identiﬁed as signiﬁcantly different across the 3 subgroups
(miR-143-3p, p ¼ 0.042, KruskaleWallis test). A signiﬁcant increase
in miR-143-3p was determined in the later sample of lower limb
onset patients, while there was a nonsigniﬁcant increase in miR-
143-3p seen in the later samples of those patients with bulbar
and upper limb onset (Fig. 5).
Table 5
Individual miRNAs and their signiﬁcance across the different disease group comparisons in the discovery study
miRNA Signiﬁcant sALS comparisons (p value)
ALS v Con ALS v Non Inﬂam ALS v Struct ALS v Myop ALS v Inﬂam ALS v MG
hsa-miR-133a-3p 0.021 0.010
hsa-miR-135b-5p 0.045
hsa-miR-143-3p 0.021 0.030 0.037 0.008
hsa-miR-144-3p 0.014 0.014 0.023
hsa-miR-146b-3p 0.042
hsa-miR-206 0.000
hsa-miR-20a-3p 0.003 0.008
hsa-miR-214-3p 0.041
hsa-miR-331-3p 0.033
hsa-miR-374b-5p 0.025
hsa-miR-518d-3p 0.035
hsa-miR-551b-3p 0.049
hsa-let-7d-5p 0.018 0.011
hsa-miR-106b-5p 0.031 0.033
hsa-miR-133b 0.020 0.020
hsa-miR-134-5p 0.034 0.004
hsa-miR-145-3p 0.002 0.020
hsa-miR-15b-5p 0.021 0.045
hsa-miR-190a-5p 0.019 0.026
hsa-miR-196b-5p 0.008 0.040
hsa-miR-301a-3p 0.017 0.018
hsa-miR-335-5p 0.049 0.028 0.014
hsa-miR-381-3p 0.050 0.020
hsa-miR-500a-3p 0.023 0.032
hsa-miR-532-3p 0.045 0.048
hsa-miR-744-5p 0.029 0.039
miRNA Signiﬁcant comparisons (p value)
Con v Non
Inﬂam
Con v
Struct
Con v
Myop
Con v
Inﬂam
Con v MG Non Inﬂam
v Struct
Inﬂam v
Non Inﬂam
Inﬂam v
Struct
Inﬂam v
Myop
Inﬂam v MG Myop v
Non Inﬂam
Myop v
Struct
MG v
Struct
MG v Myop
hsa-miR-133a-3p 0.028
hsa-miR-135b-5p 0.011 0.029
hsa-miR-144-3p 0.041
hsa-miR-206 0.002
hsa-miR-20a-3p 0.017 0.048
hsa-miR-214-3p 0.017
hsa-miR-331-3p 0.024
hsa-miR-374b-5p 0.005
hsa-miR-1 0.012 0.008 0.039
hsa-let-7d-5p 0.049 0.022 0.017
hsa-miR-106b-5p 0.021 0.023
hsa-miR-133b 0.025
hsa-miR-134-5p 0.030 0.032 0.043
hsa-miR-145-3p 0.010 0.029 0.022
hsa-miR-15b-5p
hsa-miR-190a-5p 0.026 0.013 0.003 0.049 0.016 0.043
hsa-miR-196b-5p 0.000 0.000 0.020 0.013
hsa-miR-301a-3p 0.024 0.020 0.039 0.045 0.032
hsa-miR-335-5p 0.043 0.000 0.046 0.028 0.002 0.016
hsa-miR-381-3p 0.034
For each miRNA the number of comparisons is shown and the signiﬁcance of each.
Key: ALS, amyotrophic lateral sclerosis patient group; Con, control subject group; Inﬂam, inﬂammatory neuropathy patient group; MG, myasthenia gravis patient group; miRNA, microRNA; Myop, myopathy patient group; n/a,
data not applicable; NonInﬂam, noninﬂammatory neuropathy patient group; Struct, structural spinal disorders patient group; v, versus.
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Fig. 2. Signiﬁcant miRNA expression in sALS (n ¼ 23) versus control (n ¼ 22) subjects
as conﬁrmed by qPCR. Unpaired t-test, error bars represent SD. Abbreviations: miRNA,
microRNA; sALS, sporadic amyotrophic lateral sclerosis; SD, standard deviation.
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Fig. 4. miRNA expression changes over time as conﬁrmed by qPCR in 21 sALS patients.
Unpaired t-test, error bars represent SD. Abbreviations: miRNA, microRNA; sALS,
sporadic amyotrophic lateral sclerosis; SD, standard deviation.
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The main ﬁndings of this study are; (1) miR-206, miR-143-3p,
and miR-374b-5p are differentially expressed in the serum of sALS
patients compared to control subjects; (2) the drug riluzole has no
effect on the expression of the 3 validated miRNAs in the serum of
sALS patients; and (3) miR-143-3p is signiﬁcantly increased while
miR-374b-5p is signiﬁcantly decreased in the serum of sALS
patients over time identifying a continuingly altered miRNA proﬁle
associated with disease progression.
Identifying serum-based miRNAs as potential biomarkers could
increase our understanding of ALS and this approach has been
utilized in developing the understanding of many other neurode-
generative diseases (Ding et al., 2016; Jia and Liu, 2016; Wu et al.,
2015). Serum collection comes from a routine, noninvasive blood
test making it an ‘easier’ sample to obtain from patients. Several
studies have identiﬁed potential biomarkers in serum from ALS
patients but this is the ﬁrst longitudinal study investigating miRNA
expression levels over time associated with disease progression in
human subjects.
Previous animal work has identiﬁed an increased expression of
miR-206 over time in the ALS SOD1 G93A mouse model (Toivonen
et al., 2014) and the murine spinal muscular atrophy model
(Valsecchi et al., 2015), correlating with increasing pathology and
associated muscle denervation. However, the expression of miR-
206 presented in this current study did not identify a signiﬁcant
change over time with human disease progression, yet did show an
increased expression of this miRNA in sALS patients compared tomiR-206 miR-143-3p miR-374b-5p
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Fig. 3. Riluzole versus riluzole naïve patients. miRNA expression (miR-206, miR-
143-3p and miR-374b-5p) in riluzole naïve (n ¼ 10) and riluzole treated patients
(n ¼ 13) conﬁrmed by qPCR. Unpaired t-test, error bars represent SD. Abbreviations:
miRNA, microRNA; SD, standard deviation.controls. This supports human work carried out by Toivonen et al.
(2014) where samples were however, taken at only a single time
point.
Despite these differences relating to miR-206 expression, the
current study does identify an increase in miR-143-3p and
decrease in miR-374b-5p over time, with serum samples taken
from individual sALS patients at diagnosis and at a later time
point. It would appear that such miRNA expression data could
be utilized to monitor disease progression and ultimately,
through miRNA target analysis, therapeutics could potentially
be developed where miR-143-3p and miR-374b-5p are used as
biomarkers to assess treatment efﬁcacy and potentially disease
prognosis.
During development or as a mature miRNA, miR-143-3p has
previously been identiﬁed to bind to TDP-43 in vitro (Freischmidt
et al., 2013). In contrast to our current ﬁndings, Freischmidt
reported miR-143-3p as signiﬁcantly downregulated in serum
from a subset of sALS patients. This difference could result from
alternative RNA isolation and qPCR protocols used relative to our
current study (Freischmidt et al., 2013; Hammerle-Fickinger et al.,
2010). In addition, speciﬁc information on patient sampleBu
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Fig. 5. Comparing miR-143-3p expression changes over time in 3 patient groups as
conﬁrmed by qPCR in bulbar (n ¼ 5), upper (n ¼ 6), and lower limb (n ¼ 9) onset sALS
patients. ManneWhitney U test, error bars represent SD. Abbreviations: sALS, sporadic
amyotrophic lateral sclerosis; SD, standard deviation.
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in expression between the studies (Freischmidt et al., 2013).
As described for miR-206, miR-143-3p has been implicated with
muscle changes. Investigations carried out on an immortalized
mouse myoblast cell line (C2C12 cell line) demonstrated that an
upregulation of miR-143-3p was negatively associated with
myoblast cell differentiation suggesting that miR-143-3p may
supress myotube differentiation and maturation. Furthermore it
has been proposed that inhibiting miR-143-3p may have beneﬁcial
effects in muscle wasting diseases (Du et al., 2016). The longitudinal
increased expression of miR-143-3p in the serum of sALS patients
may correlatewith increasing denervation of muscle during disease
progression. In addition, an alternative study carried out on the
same cell line identiﬁed that over-expression of miR-374b impaired
C2C12 cell differentiation, while inhibiting miR-374b expression by
20-O-methyl antisense oligonucleotides, promoted C2C12 cell dif-
ferentiation (Ma et al., 2015). In the current study miR-374b-5p is
reduced in patient serum over time. This could be a compensatory
effect to the degeneration of muscle in ALS and an attempt to
restore a balance and support muscle regeneration by promoting
myoblast differentiation.
As both miR-143-3p and miR-374b-5p show opposing expres-
sion proﬁles in processes linked to cell differentiation, the previous
cell culturework, in combinationwith the current study, provide an
explanation as to the possible consequences of the opposingmiRNA
expression over time in ALS. Decreasing expression of miR-374b-5p
may promote myoblast differentiation to compensate for the
muscle degeneration associated with ALS and the increased
expression of miR-143-3p over time reﬂecting progressive muscle
denervation associated with disease progression.
The relationship between these validated miRNA with muscle
has also been described in a study exploring the association
between endothelial cells and smooth muscle cells with miR-
143-3p seen as part of the process (Wang et al., 2016). Artiﬁ-
cially overexpressing miR-143/145 was seen to alter the levels of
metabolites involved in energy production, DNA methylation, and
oxidative stress, all processes involved in the pathobiology
ALS (Wang et al., 2016).
Selection of miRNAs for validation was based on the discovery
work carried out in the initial stage of the current study. Twelve
miRNAs were selected for validation because of their signiﬁcance
in sALS versus control subjects while the other 14 miRNAs were
chosen based on their differential expression in sALS versus
“mimic” diseases. The validation study concentrated on investi-
gating sALS compared to control subjects using the 3 validated
miRNAs from the original discovery study patient cohort. Another
9 differentially expressed miRNAs identiﬁed were not validated in
the additional patient cohort. There are a number of potential
explanations for this. As an overall function of miRNAs is to
generate rapid and reversible responses their expression is inev-
itably inﬂuenced by outside stresses beyond our control such as
the diet and lifestyle choices of the patients. For example, changes
in miRNA expression and function as a result of speciﬁc dietary
compounds such as amino acids, carbohydrates, fatty acids, and
vitamins have been reported (Garcia-Segura et al., 2013). Patient
recruitment criteria were slightly different for the validation
patient cohort compared with the original discovery study, with
samples not necessarily being taken following overnight fasting
which may account for the lack of validation of some miRNAs.
However, where possible conditions were kept the same for
patient sampling between each cohort, including samples being
taken within 3 months of diagnosis for both the discovery and
validation cohorts.
We demonstrated in the current study that riluzole did not have
an effect on the expression of the 3 validated miRNA in our patientsamples. This is the ﬁrst study to investigate the potential effect of
riluzole on miRNA expression levels in sALS patients. However, it
has to be acknowledged that there are further considerations
concerning the potential use of miRNA as biomarkers for diseases
such as ALS including the recognition that changes in the expres-
sion of circulating miRNAs may result from factors unrelated to the
disease state including variations in nutrition, medication, and
environmental factors (Castro-Villegas et al., 2015; Summerer et al.,
2013; Wang et al., 2009).
5. Conclusions
In summary, the current study, for the ﬁrst time, demonstrates
the potential use of serum-based miRNAs as biomarkers of ALS
disease progression. Importantly this study suggests that an alter-
ation in circulating serum miRNAs in ALS may result from muscle
denervation and degeneration and therefore measuring these
levels throughout a patient’s disease course could prove useful in
monitoring disease progression and therapeutic responses.
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